VIVO 16.85 Meridian Bioscience Inc $VIVO Hit a 52 week low of 16.55 Currently at 16.85 -1.06 -5.92% With a day low of 16.55 and a total volume of 813,200.
VIVO Meridian Bioscience Inc Recent Headline News
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.85 (-1.06)
Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.85 (-1.06)
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.85 (-1.06)
Meridian Bioscience Down 9.6% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Thu Oct 23, 9:58AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 2 months, Meridian Bioscience has returned 9.61% as of today's recent price of $17.72.
VIVO: 16.85 (-1.06)
Meridian Bioscience Offers Testing Solutions to Premier - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 12:50PM CDT
The illumigene molecular system uses loop-mediated isothermal DNA amplification technology, which is an efficient system to allow Meridian Bioscience (VIVO) to provide customers the illumipro 10 instrument without a capital investment or costly annual service contract.
ICUI: 71.16 (-0.89), SMA: 9.27 (-0.21), VIVO: 16.85 (-1.06), ABAX: 51.63 (-2.21)
Meridian Bioscience's Earnings Outlook Show Flat Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:40PM CDT
Meridian Bioscience (VIVO) also expects net revenues to grow in the range of 2 to 5% to approximately between $193 and $200 million for fiscal 2015.
ICUI: 71.16 (-0.89), SMA: 9.27 (-0.21), VIVO: 16.85 (-1.06), ABAX: 51.63 (-2.21)
Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Business Wire - Wed Sep 03, 6:30AM CDT
Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene(R) molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.
VIVO: 16.85 (-1.06), PINC: 32.73 (-0.70)
Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
Business Wire - Tue Sep 02, 6:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2015 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.2 million at fiscal 2014 year end to 42.4 million at fiscal 2015 year end. The revenues and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015.
VIVO: 16.85 (-1.06)
3 Value Stocks to Consider for Your Portfolio
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 12:32PM CDT
Just as we often examine companies that may be rising past their fair values, we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it...
VIVO: 16.85 (-1.06), RIG: 29.71 (-0.21), BAGL: 20.23 (-0.01)
Meridian Bioscience partners with University of Tennessee Research Foundation to develop electrokinetic sensor technology
M2 - Thu Aug 07, 6:58AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) announced on Wednesday that it executed a technology and commercial license agreement for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.85 (-1.06)
Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
Business Wire - Wed Aug 06, 8:00AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.85 (-1.06)
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
BSX: 13.24 (-0.12), VIVO: 16.85 (-1.06), ALR: 39.37 (-0.70), OSUR: 8.98 (-0.03)
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
VIVO: 16.85 (-1.06)
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 24, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
VIVO: 16.85 (-1.06), EBAY: 53.51 (+0.25), RTEC: 9.10 (-0.03)
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
SRDX: 20.44 (-0.56), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), COV: 92.08 (-0.52)
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
BSX: 13.24 (-0.12), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), STJ: 64.76 (-1.28)
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
SRDX: 20.44 (-0.56), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), STJ: 64.76 (-1.28)
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
SRDX: 20.44 (-0.56), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), COV: 92.08 (-0.52)
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VIVO: 16.85 (-1.06)
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
SRDX: 20.44 (-0.56), PRGO: 155.77 (+3.28), VIVO: 16.85 (-1.06), TTHI: 6.43 (-0.01)
VIVO Meridian Bioscience Inc Recent Headline News
Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.85 (-1.06)
Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.85 (-1.06)
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.85 (-1.06)
Meridian Bioscience Down 9.6% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Thu Oct 23, 9:58AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 2 months, Meridian Bioscience has returned 9.61% as of today's recent price of $17.72.
VIVO: 16.85 (-1.06)
Meridian Bioscience Offers Testing Solutions to Premier - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 12:50PM CDT
The illumigene molecular system uses loop-mediated isothermal DNA amplification technology, which is an efficient system to allow Meridian Bioscience (VIVO) to provide customers the illumipro 10 instrument without a capital investment or costly annual service contract.
ICUI: 71.16 (-0.89), SMA: 9.27 (-0.21), VIVO: 16.85 (-1.06), ABAX: 51.63 (-2.21)
Meridian Bioscience's Earnings Outlook Show Flat Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:40PM CDT
Meridian Bioscience (VIVO) also expects net revenues to grow in the range of 2 to 5% to approximately between $193 and $200 million for fiscal 2015.
ICUI: 71.16 (-0.89), SMA: 9.27 (-0.21), VIVO: 16.85 (-1.06), ABAX: 51.63 (-2.21)
Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Business Wire - Wed Sep 03, 6:30AM CDT
Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene(R) molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.
VIVO: 16.85 (-1.06), PINC: 32.73 (-0.70)
Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
Business Wire - Tue Sep 02, 6:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2015 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.2 million at fiscal 2014 year end to 42.4 million at fiscal 2015 year end. The revenues and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015.
VIVO: 16.85 (-1.06)
3 Value Stocks to Consider for Your Portfolio
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 12:32PM CDT
Just as we often examine companies that may be rising past their fair values, we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it...
VIVO: 16.85 (-1.06), RIG: 29.71 (-0.21), BAGL: 20.23 (-0.01)
Meridian Bioscience partners with University of Tennessee Research Foundation to develop electrokinetic sensor technology
M2 - Thu Aug 07, 6:58AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) announced on Wednesday that it executed a technology and commercial license agreement for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.85 (-1.06)
Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
Business Wire - Wed Aug 06, 8:00AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.85 (-1.06)
Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
BSX: 13.24 (-0.12), VIVO: 16.85 (-1.06), ALR: 39.37 (-0.70), OSUR: 8.98 (-0.03)
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
VIVO: 16.85 (-1.06)
3 Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 24, 12:45PM CDT
Just as we examine companies each week that may be rising past their fair values , we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think...
VIVO: 16.85 (-1.06), EBAY: 53.51 (+0.25), RTEC: 9.10 (-0.03)
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
SRDX: 20.44 (-0.56), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), COV: 92.08 (-0.52)
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
BSX: 13.24 (-0.12), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), STJ: 64.76 (-1.28)
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
SRDX: 20.44 (-0.56), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), STJ: 64.76 (-1.28)
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
SRDX: 20.44 (-0.56), VIVO: 16.85 (-1.06), ENZY: 6.84 (+0.09), COV: 92.08 (-0.52)
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
VIVO: 16.85 (-1.06)
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
SRDX: 20.44 (-0.56), PRGO: 155.77 (+3.28), VIVO: 16.85 (-1.06), TTHI: 6.43 (-0.01)
